1. Scrip
  2. >>Business
  3. >>Earnings

Takeda Stresses Orexin Commitment Despite Setback

Big Share Buyback As Q2 Reported

 
• By Ian Haydock

Fiscal Q2 figures in line with expectations but investors digest surprise trial halt and share buyback. 

narcolepsy
Takeda looks to hold up orexin franchise after recent trial halt • Source: Alamy

Takeda Pharmaceutical Co. Ltd.’s results for the fiscal first half ended 20 September appeared to much as expected and generally in line with most analysts’ predictions, as the Japanese major also confirmed its fiscal year 2021 management guidance.

But there were two major surprises in the form of a JPY100bn ($880m) share buyback and the Phase II-stage discontinuation of narcolepsy drug

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

More from Business